Steven G. Terra

Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity

Wuyan Zhang, Steven G. Terra, Edward A. Weinstein, Candace Bramson et autres

BACKGROUND: Rebound of coronavirus disease 2019 (COVID-19) is defined as return of symptoms and/or viral positivity after resolution of the initial infection. While rebound is typically mildly symptomatic and rarely associated with progression to severe disease, the benefit of repeated antiviral treatment …

us, gb, it (code pays fourni par la source)

Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial

Edward A. Weinstein, Roger Paredes, Annie Gardner, Mary Almas et autres

us, es, it, mx (code pays fourni par la source)

A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides

Xiaojie Wu, Jicheng Yu, Beikang Ge, Jeffrey Wang et autres

BACKGROUND: -conjugated antisense oligonucleotide targeting angiopoietin-like 3 (ANGPTL3) mRNA shown to reduce atherogenic lipoproteins in individuals with dyslipidemia. OBJECTIVES: The aim of this study was to satisfy Chinese regulatory requirements and support ethnic sensitivity assessment by evaluating pharmacokinetics (PK), pharmacodynamics (PD), and …

cn, in, us (code pays fourni par la source)

Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial

André Zimerman, Stephen D. Wiviott, Jeong‐Gun Park, Sabina A. Murphy et autres

AIMS: Remnant cholesterol and very low-density lipoprotein cholesterol (VLDL-C) are increasingly recognized risk factors for atherosclerotic disease with few therapeutic options. Angiopoietin-like 3 (ANGPTL3), a key protein in the metabolism of triglyceride-rich lipoproteins, is a promising target. METHODS AND RESULTS: TRANSLATE-TIMI 70 …

us, ca, pl (code pays fourni par la source)

US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients

Mark R. Cullen, Xiaofeng Zhou, Scott P. Kelly, Caihua Liang et autres

Purpose: We describe nirmatrelvir/ritonavir (NMV/r) effectiveness in preventing hospitalization among COVID-19 patients at high risk of severe disease. Methods: An ongoing US population-based observational cohort study with retrospective and prospective collection of national electronic healthcare data collected from the US Optum® deidentified …

in, us (code pays fourni par la source)

Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3

André Zimerman, Stephen D. Wiviott, Jeong‐Gun Park, Sabina A. Murphy et autres

us, ca, pl (code pays fourni par la source)

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies

Jae Eun Ahn, Steven G. Terra, Jing Liu

Vupanorsen (PF-07285557) is a second-generation ligand-conjugated 2'O-methoxyethyl modified antisense oligonucleotide designed to target angiopoietin-like 3 (ANGPTL3) mRNA expressed by the liver, shown to reduce lipids and apolipoproteins in subjects with dyslipidemia. Using pooled data from two phase I studies of participants with …

us (code pays fourni par la source)

A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

Kei Fukuhara, Kenichi Furihata, Nobushige Matsuoka, Rio Itamura et autres

Abstract Vupanorsen (PF‐07285557) is a second‐generation tri‐N‐acetyl galactosamine (GalNAc3)‐antisense oligonucleotide targeted to angiopoietin‐like 3 (ANGPTL3) mRNA, shown to reduce lipids and apolipoproteins in subjects with dyslipidemia. To aid bringing innovative drugs to global patients efficiently, a multi‐purpose Japanese phase I study was …

jp, us, in (code pays fourni par la source)

HEPATIC FAT CHANGES AFTER AN ANTISENSE OLIGONUCLEOTIDE THERAPY TARGETING ANGPTL3: A TRANSLATE-TIMI 70 ANALYSIS

André Zimerman, Stephen D. Wiviott, Jeong‐Gun Park, Sabina A. Murphy et autres

us (code pays fourni par la source)

Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study

Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li et autres

Abstract Objectives The aim of this analysis was to describe nirmatrelvir/ritonavir real-world effectiveness in preventing hospitalization among high-risk US COVID-19 patients during SARS-CoV-2 Omicron predominance. Design An ongoing population-based cohort study with retrospective and prospective collection of electronic healthcare data in the …

us (code pays fourni par la source)

Reductions in VLDL and remnant cholesterol through inhibition of ANGPTL3 protein synthesis: An analysis from TRANSLATE-TIMI 70

Nicholas Marston, Brian A. Bergmark, Candace Bramson, Madelyn Curto et autres

us, ca, pl (code pays fourni par la source)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

Darren K. McGuire, Weichung Shih, Francesco Cosentino, B Charbonnel et autres

Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. Objective: To perform meta-analyses that assess the CV and kidney outcomes of all 4 available SGLT2 inhibitors in patients …

us, se, fr, ca (code pays fourni par la source)